JUNS Stock Forecast: Jupiter Neurosciences, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 14 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Jupiter Neurosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (83): Reported profit is backed by cash, and the company is not expanding recklessly.
Issuance (5): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
JUNS stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on JUNS, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
JUNS appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
JUNS analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 25.2×
- Price / book
- —
- EV / EBITDA
- —
Cheaper than 7% of US stocks
- Revenue growth (YoY)
- 30.0%
- Earnings growth (YoY)
- —
- Gross margin
- 86.9%
- Operating margin
- —
- Net margin
- —
Higher than 78% of US stocks
Higher than 95% of US stocks
- Return on equity
- —
- Return on assets
- −159.6%
- Dividend yield
- —
Higher than 1% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Jupiter Neurosciences, Inc. has a market value of $1.6M and an enterprise value of $1.4M.
Revenue in the twelve months to 30 June 2026: $65K.
Net income over the same four quarters: −$9.2M, a −14220.1% net margin.
Free cash flow in the twelve months to 30 June 2026: −$7.2M.
forward P/E: 20.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Jupiter Neurosciences, Inc. employs 5 people — $13K of revenue per employee.
Data provided by Twelve Data
JUNS and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at JUNS’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Jupiter Neurosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about JUNS
How does Ticker Nerd's model rank JUNS?
As at 21 Nov 2026, Jupiter Neurosciences, Inc. ranks 14 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (83 of 100).
What is the JUNS stock forecast for 2030?
No analyst covering Jupiter Neurosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for JUNS are extrapolating price history, which says nothing about the business.
What does Jupiter Neurosciences, Inc. do?
Jupiter Neurosciences Inc. is a clinical-stage pharmaceutical company focused on developing therapies for neuroinflammation, central nervous system disorders, and selected rare diseases. Its work centers on JOTROL, an enhanced oral resveratrol formulation designed for pharmaceutical use across conditions such as Parkinson’s disease, Alzheimer’s disease, and other neurological disorders.
About Jupiter Neurosciences, Inc.
Jupiter Neurosciences Inc. is a clinical-stage pharmaceutical company focused on developing therapies for neuroinflammation, central nervous system disorders, and selected rare diseases. Its work centers on JOTROL, an enhanced oral resveratrol formulation designed for pharmaceutical use across conditions such as Parkinson’s disease, Alzheimer’s disease, and other neurological disorders. The company also operates a premium nutritional supplements segment through the Nugevia brand, which includes consumer products positioned around longevity, cognitive support, and wellness. Jupiter Neurosciences Inc. combines drug development with consumer health offerings, giving it a presence in both the biopharmaceutical and nutritional supplement markets. Headquartered in Jupiter, Florida, the company is organized around research, formulation technology, and commercial product development in the health sciences sector.
CEO Mr. Christer Rosen · 5 employees · United States · https://jupiterneurosciences.com